Life sciences company Bio-Techne (NASDAQ:TECH) in Q3 CY2025, with sales falling 1% year on year to $286.6 million. Its non-GAAP profit of $0.42 per share was in line with analysts’ consensus estimates ...
Bio-Techne (NASDAQ:TECH) will release its quarterly earnings report on Wednesday, 2025-11-05. Here's a brief overview for investors ahead of the announcement. Analysts anticipate Bio-Techne to report ...
Life sciences company Bio-Techne (NASDAQ:TECH) reported Q4 CY2025 results , but sales were flat year on year at $295.9 million. Its non-GAAP profit of $0.46 per share was 5.8% above analysts’ ...
Bio-Techne (NASDAQ:TECH) will release its quarterly earnings report on Wednesday, 2024-10-30. Here's a brief overview for investors ahead of the announcement. Analysts anticipate Bio-Techne to report ...
Bio-Techne TECH shares ended the last trading session 10.8% higher at $54.07. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the session. This ...
Dr. Matt McManus to transition from his role as President, Diagnostics and Spatial Biology Segment, effective March 1, 2026 Steve Crouse, Senior Vice President of Bio-Techne's Analytical Solutions ...
WOBURN, Mass.--(BUSINESS WIRE)--Spear Bio, a biotechnology company pioneering homogeneous ultrasensitive immunoassay technology, is pleased to announce a strategic distribution partnership with ...
A large exercise of company stock options by Robert V Baumgartner, Director at Bio-Techne TECH was disclosed in a new SEC filing on August 27, as part of an insider exercise. What Happened: A notable ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results